Arcus Biosciences Reports Strong Casdatifan Data, Eyes $5B Peak Sales Opportunity — Arcus Biosciences, Inc.

Event summary

Arcus Biosciences reported updated data for casdatifan, showing a 45.2% cORR and 15.1-month mPFS in the 100mg QD cohort of late-line ccRCC.
The company aims to initiate a Phase 3 study for casdatifan by the end of 2026, targeting a $5B peak sales opportunity in IO-experienced and first-line settings.
Arcus completed enrollment for the PRISM-1 Phase 3 trial of quemliclustat in pancreatic cancer, with results expected in early 2027.
The company expects to advance its first inflammation program into clinical development in 2026.

The big picture

Arcus Biosciences is positioning casdatifan as a potential best-in-class HIF-2a inhibitor, with strong data supporting its profile in ccRCC. The company's focus on combination therapies and rapid enrollment timelines reflects broader industry trends toward targeted cancer treatments. With a cash runway extending into 2028, Arcus has the financial flexibility to pursue multiple high-value opportunities in both oncology and inflammation.

What we're watching

Clinical Execution: Whether Arcus can meet its aggressive timeline for initiating a Phase 3 study by the end of 2026.
Market Opportunity: The pace at which casdatifan can capture the $5B peak sales opportunity in ccRCC.
Pipeline Diversification: How Arcus's emerging inflammation portfolio will impact its long-term strategy and valuation.